公开(公告)号：EP1687030A2

公开(公告)日：2006-08-09

申请号：EP04797931.5

申请日：2004-11-16

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： HOLMES, David, Grenville

IPC分类号： A61K45/06 ,  A61K31/4025 ,  A61K31/40 ,  A61K31/401 ,  A61P3/00 ,  A61P9/00 ,  A61P17/00 ,  A61P27/00

CPC分类号： A61K45/06 ,  A61K31/137 ,  A61K31/40 ,  A61K31/401 ,  A61K31/4025 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4704 ,  A61K2300/00

摘要： The present invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising of a DPP IV inhibitor or a pharmaceutically acceptable salt thereof and an antiobesity agent, or an appetite regulating agent, or a pharmaceutically acceptable salt thereof.. The present invention furthermore relates to the use of such a combination for the prevention, delay of progression or treatment of diseases and disorders selected from the group consisting of hypertension, congestive heart failure, left ventricular hypertrophy, peripheral arterial disease, diabetes, especially type 2 diabetes mellitus, diabetic retinopathy, macular degeneration, cataract, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, syndrome X, premenstrual syndrome, coronary heart disease, angina pectoris, thrombosis, atherosclerosis, myocardial infarction, transient ischemic attacks, stroke, vascular restenosis, hyperglycemia, hyperinsulinemia, hyperlipidemia, hypertryglyceridemia, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance, conditions of impaired fasting plasma glucose, obesity, erectile dysfunction, skin and connective tissue disorders, foot ulcerations and ulcerative colitis, endothelial dysfunction and impaired vascular compliance.

公开(公告)号：EP1671950A1

公开(公告)日：2006-06-21

申请号：EP04773379.5

申请日：2004-09-16

申请人： Sumitomo Chemical Company, Limited

发明人： TOMIGAHARA, Yoshitaka ,  HIGASHI, Kiyoshi ,  TAKAHASHI, Junya

IPC分类号： C07D213/69 ,  C07D309/38 ,  C07D311/56 ,  C07D413/10 ,  C07D407/10 ,  C07D215/22 ,  A61K31/366 ,  A61K31/37 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/4704 ,  A61K31/5377 ,  A61P43/00 ,  A61P17/14 ,  A61P1/16 ,  A61P11/00 ,  A61P13/12 ,  A61P17/02 ,  A61P9/10 ,  A61P9/12

CPC分类号： A61K8/498 ,  A61K8/4926 ,  A61K31/366 ,  A61K31/37 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/4704 ,  A61K31/5377 ,  A61Q7/00 ,  C07D311/56

摘要： The present invention relates to a cinnamoyl compound represented by the formula (I):

摘要翻译： 本发明涉及由式（I）表示的肉桂酰基化合物：

公开(公告)号：EP1553922A1

公开(公告)日：2005-07-20

申请号：EP03738060.7

申请日：2003-06-18

申请人： CHIESI FARMACEUTICI S.p.A.

发明人： CHURCH, Tanya, Kathleen ,  LEWIS, David, Andrew ,  GANDERTON, David ,  MEAKIN, Brian, John ,  BRAMBILLA, Gaetano

IPC分类号： A61K9/12 ,  A61K31/05 ,  A61K31/11 ,  A61K31/135 ,  A61P11/06 ,  A61P11/08

CPC分类号： A61K9/008 ,  A61K31/4704 ,  A61K31/485 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to a pharmaceutical formulation for use in the administration of a long-acting β2-agonist by inhalation. In particular this invention relates to a chemically stable, highly efficient salmeterol HFA solution formulation to be administered by pressurised metered dose inhalers (pMDIs) characterized by a deep lung penetration. The invention also relates to methods for the preparation of said formulation and to its use in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).

公开(公告)号：EP1418896A2

公开(公告)日：2004-05-19

申请号：EP02717729.4

申请日：2002-03-25

申请人： Vivus, Inc.

发明人： WILSON, Leland, F. ,  DOHERTY, Paul, C., Jr. ,  PLACE, Virgil, A. ,  SMITH, William, L. ,  ABDEL-HAMID ABDOU ALI, Ibrahim, AbouBakr

IPC分类号： A61K31/00 ,  A61K31/505 ,  A61K31/40 ,  A61P15/00

CPC分类号： A61K9/0031 ,  A61K9/0056 ,  A61K9/006 ,  A61K31/00 ,  A61K31/343 ,  A61K31/381 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/4164 ,  A61K31/4166 ,  A61K31/426 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4704 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/505 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/538 ,  A61K31/549 ,  A61K31/5513 ,  A61K45/06

摘要： A method is provided for treatment of premature ejaculation by administration of a phosphodiesterase inhibitor, e.g., an inhibitor of a Type III, Type IV, or Type V phosphodiesterase. In a preferred embodiment, administration is on as 'as needed' basis, i.e., the drug is administered immediately or several hours prior to sexual activity. Pharmaceutical formulations and packaged kits are also provided.

公开(公告)号：EP1398040A1

公开(公告)日：2004-03-17

申请号：EP02728121.1

申请日：2002-05-23

申请人： OTSUKA PHARMACEUTICAL CO., LTD.

发明人： TOMOHIRA, Yuso

IPC分类号： A61K47/32 ,  A61K9/22 ,  A61K9/52 ,  A61K31/522 ,  A61K47/14 ,  A61K47/38 ,  A61P11/06

CPC分类号： A61K31/496 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1652 ,  A61K31/4704 ,  A61K31/4709 ,  A61K31/522

摘要： The present invention provides a medicinal composition that exhibits excellent storage stability and, even over long-term storage, little change in the release rate of the pharmacologically active substance contained therein. The medicinal composition of the invention prepared by dissolving or dispersing a pharmacologically active substance and a pH-independent water-insoluble polymer in a molten low-melting substance, and which can be prepared by spraying a liquid substance, obtained by dissolving or dispersing the pharmacologically active substance in a molten mixture comprising the low-melting substance and the pH-independent water-insoluble polymer, and then cooling the liquid substance.

摘要翻译： 通过将活性物质和与pH无关的水不溶性聚合物溶解或分散在熔融的低熔点物质中来制备药物组合物。

公开(公告)号：EP1270006B1

公开(公告)日：2004-02-04

申请号：EP02013500.0

申请日：2002-06-17

申请人： DAINIPPON INK AND CHEMICALS, INC.

发明人： Kubota, Ryuji ,  Araya, Hiroshi ,  Obata, Kouki ,  Kimura, Nobuyuki ,  Fukui, Hiroyuki ,  Takagaki, Hidetsugu

IPC分类号： A61K31/4704 ,  A61K9/16 ,  A61K9/20

CPC分类号： A61K31/4704 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/205 ,  A61K9/2054

公开(公告)号：EP1339407A1

公开(公告)日：2003-09-03

申请号：EP01998349.3

申请日：2001-11-20

申请人： JANSSEN PHARMACEUTICA N.V.

发明人： END, David, William ,  BOWDEN, Charles, Ronald

IPC分类号： A61K31/47 ,  A61P1/00

CPC分类号： A61K31/4704

摘要： The present invention relates to the use of certain farnesyl protein transferaseinhibitors for the manufacture of a medicament for the treatment of inflammatory bowel disease.

公开(公告)号：EP1237577A2

公开(公告)日：2002-09-11

申请号：EP00986297.0

申请日：2000-12-08

申请人： Vivus, Inc.

发明人： DOHERTY, Paul, C., Jr. ,  PLACE, Virgil A. ,  SMITH, William, L.

IPC分类号： A61K45/06 ,  A61K45/08 ,  A61K9/00

CPC分类号： A61K9/0034 ,  A61K9/0031 ,  A61K9/0056 ,  A61K9/006 ,  A61K31/00 ,  A61K31/343 ,  A61K31/381 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/4164 ,  A61K31/4166 ,  A61K31/426 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4704 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/505 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/538 ,  A61K31/549 ,  A61K31/5513 ,  A61K45/06

摘要： A method is provided for treating erectile dysfunction in a mammalian male individual. The method involves the transmucosal administration of a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, within the context of an effective dosing regimen. Preferred modes of administration include transbuccal, sublingual and transrectal routes. Pharmaceutical formulations and kits are provided as well.

公开(公告)号：EP1039884A1

公开(公告)日：2000-10-04

申请号：EP98959929.5

申请日：1998-12-11

申请人： ORION CORPORATION

发明人： HAIKALA, Heimo ,  KAHEINEN, Petri ,  LEVIJOKI, Jouko ,  KAIVOLA, Juha ,  OVASKA, Martti ,  PYSTYNEN, Jarmo

IPC分类号： A61K31/00

CPC分类号： A61K31/501 ,  A61K31/00 ,  A61K31/352 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/4704 ,  A61K31/4709

摘要： A method for the prevention and treatment of stunning of the heart subsequent to ischemia-reperfusion is described. The method comprises administering a therapeutically effective amount of a phospholamban inhibitor to a patient. Phospholamban inhibitors relieve the inhibitory effect of phospholamban on cardiac sarcoplasmic reticulum Ca2+-ATPase.

公开(公告)号：EP1027054A1

公开(公告)日：2000-08-16

申请号：EP98954032.3

申请日：1998-10-28

申请人： Vivus, Inc.

发明人： DOHERTY, Paul, C., Jr. ,  PLACE, Virgil, A. ,  SMITH, William, L.

IPC分类号： A61K31/485 ,  A61K31/47 ,  A61K31/50 ,  A61K31/505

CPC分类号： A61K45/06 ,  A61K9/0034 ,  A61K31/00 ,  A61K31/343 ,  A61K31/381 ,  A61K31/4015 ,  A61K31/4164 ,  A61K31/4166 ,  A61K31/426 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4704 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/538 ,  A61K31/549 ,  A61K31/5513

摘要： A method is provided for treating erectile dysfunction in a mammalian male individual. The method involves the local administration of a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, within the context of an effective dosing regimen. A preferred mode of administration is transurethral. Pharmaceutical formulations and kits are provided as well.